Melbourne, May 13, 2026, 07:35 AEST
- CSL closed Tuesday at A$98.55, down 2.18%, after Monday’s 15.96% fall; the stock stayed near the A$93.64 low hit in the first wave of the sell-off.
- The move followed a 90-day review that cut FY26 revenue and profit guidance and flagged about US$5 billion in added non-cash pre-tax impairments across FY26 and FY27.
- Bulls see a low-multiple plasma leader with durable demand. Bears see another forecast reset, Vifor damage and broker targets being cut fast.
CSL is not being sold just because the number was bad. It is being sold because the latest number says the old CSL model was too generous.
The last traded price was A$98.55, with Tuesday’s range running from A$94.76 to A$100.00 on 4.66 million shares. That followed Monday’s hard break, when CSL fell 15.96% to A$100.75 after touching A$93.64. A year ago this was still treated as one of the ASX’s safest compounders; now the 52-week high sits all the way up at A$275.79.
The reason the chart moved again is straightforward. Interim chief executive Gordon Naylor finished a 90-day review and told investors FY26 revenue should be around US$15.2 billion and NPATA around US$3.1 billion at constant currency. Constant currency means the company strips out exchange-rate moves. NPATA is CSL’s preferred profit measure before acquired-IP amortisation and big one-offs such as restructuring and impairment charges.
The bigger issue was the balance sheet. CSL said it expects about US$5 billion of extra non-cash pre-tax impairments across FY26 and FY27, on top of impairments already booked at the half-year. An impairment is an accounting write-down of asset values. It does not itself use cash, but it tells investors the assets are not expected to earn what the company once assumed. In this case, the pressure is tied to CSL Vifor intangibles, product portfolio values and under-used plant and equipment.
The downgrade was not vague. CSL blamed about US$300 million of revenue impact from U.S. immunoglobulin channel inventory, about US$200 million from lower market value in China albumin, and roughly US$150 million from the Middle East conflict, revised HEMGENIX growth and competition in iron. Immunoglobulin is a plasma-derived antibody therapy used in immune-related conditions; it is one of the group’s key profit engines.
Naylor tried to draw a line under the mess, but the tone was not sugar-coated. He said CSL’s “growth initiatives are working,” yet the financial benefits would take longer to arrive. On the investor call, he also pushed back on whether CSL had lost its low-cost position, answering: “Yes, is the short answer,” while saying margins were “pretty robust” but “not as good as we’d like.”
That matters because investors had already been asked to wait. The review came after Paul McKenzie’s surprise exit and after CSL disclosed an 81% drop in first-half profit in February. ABC reported the stock was down about 41% for 2026 and more than 57% over the prior 12 months after Monday’s plunge. This is no longer one downgrade in isolation.
The bull case is still there, just thinner. CSL says U.S. immunoglobulin end demand is growing at mid- to high-single digits, and its review points to long-term unmet patient need in plasma therapies. Bulls also argue that a non-cash writedown does not kill the cash-generating core business. ETF Shares chief executive Cliff Man pointed to a price-earnings ratio of about 14 and called the stock “very cheap” given CSL’s sector position.
The bear case answers fast: cheap can get cheaper when trust breaks. Citi analyst Laura Sutcliffe almost halved her target to A$110, while Macquarie’s Christine Trinh cut hers to A$111 and described the situation as a “bloody mess.” Bell Potter moved its target to A$100, Canaccord cut its rating to hold, and Bell Potter veteran Richard Coppleson warned there is “never just one cockroach in the cupboard.” Sharecafe
The competitive read is uncomfortable for CSL. Renta 4’s analysis, cited by The Corner, said strong immunoglobulin demand at Grifols suggests CSL’s warning looks more like an internal execution problem than a broad plasma-market slump. That is the cleanest worry for shareholders: rivals such as Grifols can still point to demand strength while CSL talks about inventory, pricing and slower benefits from its own initiatives.
The damage also spilled into the local healthcare tape, though CSL was the centre of it. IG said the ASX 200 healthcare sector remained under pressure, trading near levels last seen in August 2017, with ResMed down 3.63% and Pro Medicus down 3.31% in Tuesday trade. Those are not direct plasma rivals, but they show the sector did not have much shelter once CSL reopened the earnings-risk debate.
The next test is proof, not promise. CSL has said detailed financial and operating performance will come with full-year results on August 18. Until then, the market will watch whether U.S. immunoglobulin inventory clears, China albumin pricing stabilises, Vifor stops leaking value, and the CEO search produces someone with enough authority to reset capital allocation.
For now, CSL trades less like a routine healthcare pullback and more like a former premium stock trying to find the right multiple. The assets still matter. So does the plasma franchise. But the market is asking a colder question this week: how much of the old CSL was business quality, and how much was belief?
